

# Stanford

---



## Anusha Kalbasi, M.D.

Associate Professor of Radiation Oncology (Radiation Therapy)  
Radiation Oncology - Radiation Therapy

### **CLINICAL OFFICE (PRIMARY)**

- **Radiation Oncology**
- 875 Blake Wilbur Dr
- MC 6560
- Stanford, CA 94305
- Tel** (650) 498-6000      **Fax** (650) 725-8231

### **ACADEMIC CONTACT INFORMATION**

- **Administrative Contact**
- Naomi Meurice - Assistant Clinical Research Coordinator
- Email** naomimeu@stanford.edu
- Tel** 650-498-1499

### **Bio**

---

#### **BIO**

Dr. Kalbasi is a board-certified radiation oncologist and physician-scientist at the Stanford Cancer Institute. He is also an associate professor of radiation oncology at Stanford Medicine and a project member of the Parker Institute for Cancer Immunotherapy.

In the clinic, Dr. Kalbasi specializes in the diagnosis and treatment of solid tumors, especially sarcoma and melanoma, with a focus on bringing new treatments to patients. This focus includes using advanced techniques in radiation oncology and cancer immunotherapy.

Dr. Kalbasi's NIH-funded laboratory studies the cancer-immune interface in various therapeutic contexts, including T cell therapy, cytokine therapy and innate immune agonism. The lab has described tumor cell-, T cell- and myeloid cell-intrinsic mechanisms of resistance to therapy and approaches to overcome therapy resistance. Dr. Kalbasi is also an experienced leader of clinical trials related to immunotherapy, T cell therapy and radiation therapy.

Prior to his arrival at Stanford Health Care, Dr. Kalbasi was assistant professor of radiation oncology in the David Geffen School of Medicine at UCLA and chief of sarcoma radiotherapy at the UCLA Jonsson Comprehensive Cancer Center. During his tenure, he was named a NextGen Star by the American Association of Cancer Research in recognition for excellence in cancer research.

Dr. Kalbasi's work has been published in leading journals including Nature, Science Translational Medicine, JAMA Oncology, Lancet Oncology, Nature Cancer and Cancer Discovery. He has served as a peer reviewer for multiple prestigious journals, including the Proceedings of the National Academy of Sciences, Cell and the Journal of Clinical Investigation. He has also presented research to his peers at the American Association for Cancer Research and the American Institute of Chemical Engineers.

### **CLINICAL FOCUS**

- **Radiation Oncology**

## ACADEMIC APPOINTMENTS

- Associate Professor, Radiation Oncology - Radiation Therapy
- Member, Bio-X
- Member, Stanford Cancer Institute

## HONORS AND AWARDS

- Robert L. and Mary Ellenburg Endowed Faculty Scholar, Stanford University School of Medicine
- AACR NextGen Star Award, American Association for Cancer Research
- Joseph Drown Foundation Dean's Award in Research Excellence, UCLA
- Clinical Scientist Career Development Award (K08), National Cancer Institute
- Damon Runyon Clinical Investigator Award, Damon Runyon Cancer Research Foundation
- MRA Young Investigator Award, Melanoma Research Alliance
- SITC Young Investigator Award, Society for Immunotherapy of Cancer
- SARC Career Enhancement Award, Sarcoma Alliance for Research through Collaboration
- Tower Cancer Research Foundation Young Investigator Award, Tower Cancer Research Foundation
- ASCO Merit Award, Conquer Cancer Foundation
- ASCO Young Investigator Award, Conquer Cancer Foundation
- Alpha Omega Alpha, David Geffen School of Medicine at UCLA
- HHMI Research Scholar, Howard Hughes Medical Institute
- Geffen Scholar, David Geffen School of Medicine
- Phi Beta Kappa, UCLA
- Merck Index Award, UCLA Dept. of Chemistry & Biochemistry
- Robert C. Byrd Scholar, U.S. Dept. of Education
- Regents' Scholar, UCLA

## PROFESSIONAL EDUCATION

- Board Certification: Radiation Oncology, American Board of Radiology (2017)
- Residency: University of Pennsylvania Radiation Oncology Program (2016) PA
- Internship: University of Pennsylvania Internal Medicine Residency (2012) PA
- Medical Education: UCLA David Geffen School Of Medicine Registrar (2011) CA
- B.S., UCLA , Biochemistry
- M.D., David Geffen School of Medicine at UCLA , Medicine
- Board Certification, American Board of Radiology , Radiation Oncology

## **Research & Scholarship**

---

### CLINICAL TRIALS

- Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma, Recruiting
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma, Not Recruiting

## Teaching

---

### STANFORD ADVISEES

#### Doctoral Dissertation Reader (AC)

Cort Breuer, Grayson Rodriguez

#### Postdoctoral Faculty Sponsor

Ossama Labiad, Heather Ogana

#### Doctoral Dissertation Advisor (AC)

Kayla Kulhanek

### GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Cancer Biology (Phd Program)
- Immunology (Phd Program)

## Publications

---

### PUBLICATIONS

- **IGF2BP3 as a Prognostic Biomarker in Well-Differentiated/Dedifferentiated Liposarcoma.** *Cancers*  
Klingbeil, K. D., Tang, J. P., Graham, D. S., Lofftus, S. Y., Jaiswal, A. K., Lin, T. L., Frias, C., Chen, L. Y., Nakasaki, M., Dry, S. M., Crompton, J. G., Eilber, F. C., Rao, et al  
2023; 15 (18)
- **Adopting shorter radiation regimens: rules of engagement for sarcoma.** *The Lancet. Oncology*  
Kalbasi, A.  
2023; 24 (2): e70
- **Lifelong Imaging Surveillance is Indicated for Patients with Primary Retroperitoneal Liposarcoma.** *Annals of surgical oncology*  
Eckardt, M. A., Graham, D. S., Klingbeil, K. D., Lofftus, S. Y., McCaw, T. R., Bailey, M. J., Goldring, C. J., Kendal, J. K., Kadera, B. E., Nelson, S. D., Dry, S. M., Kalbasi, A. K., Singh, et al  
2022
- **Engineered IL13 variants direct specificity of IL13R#2-targeted CAR T cell therapy.** *Proceedings of the National Academy of Sciences of the United States of America*  
Stern, L. A., Gholamin, S., Moraga, I., Yang, X., Saravanakumar, S., Cohen, J. R., Starr, R., Aguilar, B., Salvary, V., Hibbard, J. C., Kalbasi, A., Shepphard, J. K., O'Hearn, et al  
2022; 119 (33): e2112006119
- **Infrequent chromosomal loss and recurrent gains lead to imbalanced expression of HLA genes in melanoma**  
Campbell, K. M., Saco, J., Medina, E., Amouzgar, M., Pfeiffer, S. M., Gonzalez, C. R., Steiner, G., Champhekar, A., Saus, C., Zaretsky, J., Rodriguez, G., Vega-Crespo, A., Carretero, et al  
AMER ASSOC CANCER RESEARCH.2022
- **Human chimeric orthogonal IL9 receptor signaling promotes stemness and polyfunctionality for adoptive T cell therapy of cancer**  
Tariveranmoshabad, M., Su, L. L., Sun, A. L., Picton, L. K., Ribas, A., Garcia, K., Kalbasi, A.  
AMER ASSOC CANCER RESEARCH.2022
- **Potentiating adoptive cell therapy using synthetic IL-9 receptors.** *Nature*  
Kalbasi, A., Siurala, M., Su, L. L., Tariveranmoshabad, M., Picton, L. K., Ravikumar, P., Li, P., Lin, J., Escuin-Ordinas, H., Da, T., Kremer, S. V., Sun, A. L., Castelli, et al  
2022
- **Orthogonal IL-9 receptor signaling reprograms T cells to obviate conditioning chemotherapy before adoptive cell therapy.**  
Kalbasi, A., Tariveranmoshabad, M., Escuin-Ordinas, H., Kremer, S., Su, L. L., Picton, L., Parisi, A., Garcia, C., Ribas, A.

AMER ASSOC CANCER RESEARCH.2021

- **Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma.** *Science translational medicine*  
Kalbasi, A., Tariveranmoshabad, M., Hakimi, K., Kremer, S., Campbell, K. M., Funes, J. M., Vega-Crespo, A., Parisi, G., Champekar, A., Nguyen, C., Torrejon, D., Shin, D., Zaretsky, et al  
2020; 12 (565)
- **Conserved Interferon-# Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.** *Cancer cell*  
Grasso, C. S., Tsoi, J., Onyshchenko, M., Abril-Rodriguez, G., Ross-Macdonald, P., Wind-Rotolo, M., Champhekar, A., Medina, E., Torrejon, D. Y., Shin, D. S., Tran, P., Kim, Y. J., Puig-Saus, et al  
2020; 38 (4): 500-515.e3
- **Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.** *Cancer discovery*  
Torrejon, D. Y., Abril-Rodriguez, G., Champhekar, A. S., Tsoi, J., Campbell, K. M., Kalbasi, A., Parisi, G., Zaretsky, J. M., Garcia-Diaz, A., Puig-Saus, C., Cheung-Lau, G., Wohlwender, T., Krystofinski, et al  
2020; 10 (8): 1140-1157
- **A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Kalbasi, A., Kamrava, M., Chu, F. I., Telesca, D., Van Dams, R., Yang, Y., Ruan, D., Nelson, S. D., Dry, S. M., Hernandez, J., Chmielowski, B., Singh, A. S., Bukata, et al  
2020; 26 (8): 1829-1836
- **Adopting shorter radiation regimens: rules of engagement for sarcoma** *LANCET ONCOLOGY*  
Kalbasi, A.  
2020; 24 (2): E70
- **Tumour-intrinsic resistance to immune checkpoint blockade.** *Nature reviews. Immunology*  
Kalbasi, A., Ribas, A.  
2020; 20 (1): 25-39
- **SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study** *CANCER DISCOVERY*  
Ribas, A., Medina, T., Kummar, S., Amin, A., Kalbasi, A., Drabick, J. J., Barve, M., Daniels, G. A., Wong, D. J., Schmidt, E., Candia, A. F., Coffmanm, R. L., Leung, et al  
2018; 8 (10): 1250-57
- **(99)mTc-phytate as a diagnostic probe for assessing inflammatory reaction in malignant tumors** *NUCLEAR MEDICINE COMMUNICATIONS*  
Fernandes, R. S., Mota, L. G., Kalbasi, A., Moghbel, M., Werner, T. J., Alavi, A., Rubello, D., Cardoso, V. N., de Barros, A. L.  
2015; 36 (10): 1042-1048